|La Jolla Pharmaceutical Co.|
4660 La Jolla Village Drive
United States - Map
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for chronic organ failure and cancer. The companys products include GCS-100 that is in Phase II clinical trial for the treatment of chronic kidney disease. It also provides LJPC-501, a peptide agonist of the renin-angiotensin system, which is designed to help restore kidney function in patients with hepatorenal syndrome; and LJPC-401, a peptide for the treatment of iron disorders. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
|Dr. George F. Tidmarsh M.D., Ph.D.,
Chief Exec. Officer, Pres, Principal Financial Officer, Principal Accounting Officer, Sec. and Director
|Mr. Chester S. Zygmont III,
Director of Fin.
|Mr. James Rolke ,
Sr. Director of R&D
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|